Biofrontera Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Biofrontera Inc. (BFRI) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$188.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-13
- Biofrontera Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$754.00K, a 161.96% decline year-over-year.
- Biofrontera Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $566.00K, a 84.36% increase year-over-year.
- Biofrontera Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$1.66M.
- Biofrontera Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $746.00K, a 29.42% decline year-over-year.
- Biofrontera Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $610.00K.
- Biofrontera Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$230.00K.
- Biofrontera Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$6.35M.
- Biofrontera Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$3.61M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$754.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$188.00K 10-Q · filed 2026-08-13 | -$1.85M derived: sum of 3 quarters · filed 2026-08-13 | -$1.10M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $566.00K 10-Q · filed 2026-05-14 | -$1.09M derived: sum of 2 quarters · filed 2026-05-14 | -$348.00K derived: sum of 3 quarters · filed 2026-05-14 | $869.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$914.00K derived: sum of 2 quarters · filed 2026-03-19 | $303.00K derived: sum of 3 quarters · filed 2026-08-13 | $610.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $746.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.96M derived: sum of 2 quarters · filed 2026-08-13 | $2.27M 10-Q · filed 2025-11-12 | $1.88M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.52M 10-Q · filed 2026-08-13 | $1.13M derived: sum of 3 quarters · filed 2026-08-13 | $2.19M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $307.00K 10-Q · filed 2026-05-14 | -$87.00K derived: sum of 2 quarters · filed 2026-05-14 | $970.00K derived: sum of 3 quarters · filed 2026-05-14 | $338.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$394.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $663.00K derived: sum of 2 quarters · filed 2026-03-19 | $31.00K derived: sum of 3 quarters · filed 2026-03-19 | -$230.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $425.00K derived: sum of 2 quarters · filed 2025-11-12 | $164.00K 10-Q · filed 2025-11-12 | -$6.38M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$632.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$893.00K 10-Q · filed 2025-08-13 | -$7.44M derived: sum of 3 quarters · filed 2025-08-13 | -$7.14M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$261.00K 10-Q · filed 2025-05-15 | -$6.81M derived: sum of 2 quarters · filed 2025-05-15 | -$6.50M derived: sum of 3 quarters · filed 2025-05-15 | -$6.89M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$6.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$6.24M derived: sum of 2 quarters · filed 2025-03-20 | -$6.63M derived: sum of 3 quarters · filed 2025-03-20 | -$6.35M 10-K · filed 2025-03-20 |
| 2023-09-30 | $304.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$77.00K derived: sum of 2 quarters · filed 2024-11-14 | $197.00K 10-Q · filed 2024-11-14 | -$3.19M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$381.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$107.00K 10-Q · filed 2024-08-14 | -$3.50M derived: sum of 3 quarters · filed 2024-08-14 | -$3.47M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $274.00K 10-Q · filed 2024-05-15 | -$3.12M derived: sum of 2 quarters · filed 2024-05-15 | -$3.09M derived: sum of 3 quarters · filed 2024-05-15 | |
| 2022-12-31 | -$3.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$3.37M derived: sum of 2 quarters · filed 2024-03-15 | -$3.61M 10-K · filed 2024-03-15 | |
| 2022-09-30 | $24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$216.00K 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | -$240.00K 10-Q · filed 2023-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |